Literature DB >> 23863633

Radiation and immunotherapy: a synergistic combination.

Anusha Kalbasi1, Carl H June, Naomi Haas, Neha Vapiwala.   

Abstract

Immunotherapy can be an effective treatment for metastatic cancer, but a significant subpopulation will not respond, likely due to the lack of antigenic mutations or the immune-evasive properties of cancer. Likewise, radiation therapy (RT) is an established cancer treatment, but local failures still occur. Clinical observations suggest that RT may expand the therapeutic reach of immunotherapy. We examine the immunobiologic and clinical rationale for combining RT and immunotherapy, two modalities yet to be used in combination in routine practice. Preclinical data indicate that RT can potentiate the systemic efficacy of immunotherapy, while activation of the innate and adaptive immune system can enhance the local efficacy of RT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23863633      PMCID: PMC4101987          DOI: 10.1172/JCI69219

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

Review 1.  2. Dendritic cells as regulators of immunity and tolerance.

Authors:  Natalija Novak; Thomas Bieber
Journal:  J Allergy Clin Immunol       Date:  2008-02       Impact factor: 10.793

2.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

4.  Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.

Authors:  Karsten A Pilones; Noriko Kawashima; Anne Marie Yang; James S Babb; Silvia C Formenti; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

5.  Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.

Authors:  Amit A Lugade; Elizabeth W Sorensen; Scott A Gerber; James P Moran; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

7.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

8.  Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.

Authors:  Satoko Matsumura; Baomei Wang; Noriko Kawashima; Steve Braunstein; Michelle Badura; Thomas O Cameron; James S Babb; Robert J Schneider; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  Epitope landscape in breast and colorectal cancer.

Authors:  Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

10.  Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.

Authors:  Caroline Aspord; Alexander Pedroza-Gonzalez; Mike Gallegos; Sasha Tindle; Elizabeth C Burton; Dan Su; Florentina Marches; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2007-04-16       Impact factor: 14.307

View more
  118 in total

1.  Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

Authors:  Qian Zhu; Mu-Yan Cai; Chang-Long Chen; Hao Hu; Huan-Xin Lin; Min Li; De-Sheng Weng; Jing-Jing Zhao; Ling Guo; Jian-Chuan Xia
Journal:  Oncoimmunology       Date:  2017-04-27       Impact factor: 8.110

Review 2.  Immunotherapy in the Asiatic population: any differences from Caucasian population?

Authors:  Lunxi Peng; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors:  Yu Yu; Jiuwei Cui
Journal:  Oncol Lett       Date:  2018-07-26       Impact factor: 2.967

4.  Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.

Authors:  Michael A Spinner; Vanessa E Kennedy; John S Tamaresis; Philip W Lavori; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Andrew R Rezvani; Judith A Shizuru; Wen-Kai Weng; Richard T Hoppe; Samuel Strober; Robert Lowsky
Journal:  Blood Adv       Date:  2019-08-27

Review 5.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

6.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

Review 7.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

8.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

9.  Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Authors:  Abigail T Berman; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 10.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.